251 related articles for article (PubMed ID: 25355426)
1. The Wnt signalling cascade and the adherens junction complex in craniopharyngioma tumorigenesis.
Preda V; Larkin SJ; Karavitaki N; Ansorge O; Grossman AB
Endocr Pathol; 2015 Mar; 26(1):1-8. PubMed ID: 25355426
[TBL] [Abstract][Full Text] [Related]
2. Study of β-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases.
Malgulwar PB; Nambirajan A; Pathak P; Faruq M; Suri V; Sarkar C; Jagdevan A; Sharma BS; Sharma MC
J Neurooncol; 2017 Jul; 133(3):487-495. PubMed ID: 28500561
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemistry or Molecular Analysis: Which Method Is Better for Subtyping Craniopharyngioma?
Fukuhara N; Iwata T; Inoshita N; Yoshimoto K; Kitagawa M; Fukuhara H; Tatsushima K; Yamaguchi-Okada M; Takeshita A; Ito J; Takeuchi Y; Yamada S; Nishioka H
Endocr Pathol; 2021 Jun; 32(2):262-268. PubMed ID: 32965631
[TBL] [Abstract][Full Text] [Related]
4. [Implication of BRAF V600E and CTNNB1 gene mutations in the pathological classification of craniopharyngioma].
Xu SS; Wang LM; Zhao LH; He ZL; Gong LP; Lu DH; Teng LH
Zhonghua Bing Li Xue Za Zhi; 2019 Sep; 48(9):682-687. PubMed ID: 31495087
[No Abstract] [Full Text] [Related]
5. Pathology and pathogenesis of craniopharyngiomas.
Larkin SJ; Ansorge O
Pituitary; 2013 Mar; 16(1):9-17. PubMed ID: 22886701
[TBL] [Abstract][Full Text] [Related]
6. High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas.
Yoshimoto K; Hatae R; Suzuki SO; Hata N; Kuga D; Akagi Y; Amemiya T; Sangatsuda Y; Mukae N; Mizoguchi M; Iwaki T; Iihara K
Neuropathology; 2018 Feb; 38(1):3-10. PubMed ID: 28840946
[TBL] [Abstract][Full Text] [Related]
7. Characterization of novel CTNNB1 mutation in Craniopharyngioma by whole-genome sequencing.
He J; Zeng Z; Wang Y; Deng J; Tang X; Liu F; Huang J; Chen H; Liang R; Zan X; Liu Z; Tong A; Guo G; Xu J; Zhu X; Zhou L; Peng Y
Mol Cancer; 2021 Dec; 20(1):168. PubMed ID: 34922552
[TBL] [Abstract][Full Text] [Related]
8. Impact of the Canonical Wnt Pathway Activation on the Pathogenesis and Prognosis of Adamantinomatous Craniopharyngiomas.
Jucá CEB; Colli LM; Martins CS; Campanini ML; Paixão B; Jucá RV; Saggioro FP; de Oliveira RS; Moreira AC; Machado HR; Neder L; Antonini SR; de Castro M
Horm Metab Res; 2018 Jul; 50(7):575-581. PubMed ID: 29625497
[No Abstract] [Full Text] [Related]
9. Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma.
Goschzik T; Gessi M; Dreschmann V; Gebhardt U; Wang L; Yamaguchi S; Wheeler DA; Lauriola L; Lau CC; Müller HL; Pietsch T
J Neuropathol Exp Neurol; 2017 Feb; 76(2):126-134. PubMed ID: 28069929
[TBL] [Abstract][Full Text] [Related]
10. Comparative immunohistochemical expression of β-catenin, EGFR, ErbB2, and p63 in adamantinomatous and papillary craniopharyngiomas.
Esheba GE; Hassan AA
J Egypt Natl Canc Inst; 2015 Sep; 27(3):139-45. PubMed ID: 26198262
[TBL] [Abstract][Full Text] [Related]
11. Molecular and cellular pathogenesis of adamantinomatous craniopharyngioma.
Martinez-Barbera JP
Neuropathol Appl Neurobiol; 2015 Oct; 41(6):721-32. PubMed ID: 25611703
[TBL] [Abstract][Full Text] [Related]
12. Biological Behaviour of Craniopharyngiomas.
Martinez-Barbera JP; Andoniadou CL
Neuroendocrinology; 2020; 110(9-10):797-804. PubMed ID: 32126562
[TBL] [Abstract][Full Text] [Related]
13. Do craniopharyngioma molecular signatures correlate with clinical characteristics?
Omay SB; Chen YN; Almeida JP; Ruiz-Treviño AS; Boockvar JA; Stieg PE; Greenfield JP; Souweidane MM; Kacker A; Pisapia DJ; Anand VK; Schwartz TH
J Neurosurg; 2018 May; 128(5):1473-1478. PubMed ID: 28707994
[TBL] [Abstract][Full Text] [Related]
14. The molecular pathogenesis of craniopharyngiomas.
Campanini ML; Almeida JP; Martins CS; de Castro M
Arch Endocrinol Metab; 2023 Mar; 67(2):266-275. PubMed ID: 36748936
[TBL] [Abstract][Full Text] [Related]
15. Adamantinomatous craniopharyngioma: pathology, molecular genetics and mouse models.
Martinez-Barbera JP; Buslei R
J Pediatr Endocrinol Metab; 2015 Jan; 28(1-2):7-17. PubMed ID: 25503464
[TBL] [Abstract][Full Text] [Related]
16. 60 YEARS OF NEUROENDOCRINOLOGY: Biology of human craniopharyngioma: lessons from mouse models.
Martinez-Barbera JP
J Endocrinol; 2015 Aug; 226(2):T161-72. PubMed ID: 25926515
[TBL] [Abstract][Full Text] [Related]
17. Tumour cell migration in adamantinomatous craniopharyngiomas is promoted by activated Wnt-signalling.
Hölsken A; Buchfelder M; Fahlbusch R; Blümcke I; Buslei R
Acta Neuropathol; 2010 May; 119(5):631-9. PubMed ID: 20131060
[TBL] [Abstract][Full Text] [Related]
18. Targeted BRAF and CTNNB1 next-generation sequencing allows proper classification of nonadenomatous lesions of the sellar region in samples with limiting amounts of lesional cells.
Marucci G; de Biase D; Zoli M; Faustini-Fustini M; Bacci A; Pasquini E; Visani M; Mazzatenta D; Frank G; Tallini G
Pituitary; 2015 Dec; 18(6):905-11. PubMed ID: 26156055
[TBL] [Abstract][Full Text] [Related]
19. Target gene activation of the Wnt signaling pathway in nuclear beta-catenin accumulating cells of adamantinomatous craniopharyngiomas.
Hölsken A; Kreutzer J; Hofmann BM; Hans V; Oppel F; Buchfelder M; Fahlbusch R; Blümcke I; Buslei R
Brain Pathol; 2009 Jul; 19(3):357-64. PubMed ID: 18540944
[TBL] [Abstract][Full Text] [Related]
20. PROP1 and CTNNB1 expression in adamantinomatous craniopharyngiomas with or without β-catenin mutations.
Cani CM; Matushita H; Carvalho LR; Soares IC; Brito LP; Almeida MQ; Mendonça BB
Clinics (Sao Paulo); 2011; 66(11):1849-54. PubMed ID: 22086512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]